Super-enhancers: novel target for pancreatic ductal adenocarcinoma

Super-enhancers: novel target for pancreatic ductal adenocarcinoma
PDAC cells demonstrated significant binding of different enhancers in PDAC cells than non-cancerous cells, (A) Binding with SOX2, FOXO-1, CDX-2, KLF-4, MED-1, PARD6B, KLF-7, MYC, OCT-4, SOX-9, USP12, INPP5D and (C) with SHH pathway using ChIP-Seq with the H3K27me3 antibody. (B and D) TCGA data also suggested a higher expression of those genes in PDAC compared with normal tissue. Credit: Animesh Dhar

Differential H3K27AC marks were identified at enhancer regions of genes including c-MYC, MED1, OCT-4, NANOG, and SOX2 that can act as super-enhancers (SE), cluster of genes in non-cancerous, cancerous and metastatic PDAC cell lines. GZ17-6.02 affects acetylation of the genes, reduces transcription of major transcription factors, sonic hedgehog pathway proteins, and stem cell markers.

Dr. Animesh Dhar from the Department of Cancer Biology, KU Cancer Center, the University of Kansas Medical Center in Kansas City, KS USA said, "Pancreatic ductal adenocarcinoma is a lethal malignancy and is the fourth leading cause of -related mortality in the USA, due to its susceptibility to metastasis."

The research revealed how alteration in the transcription and enhancer landscape takes place during discrete stages of disease progression in PDAC mouse model. Thus, identifying novel therapeutic agents targeting enhancers related to disease progression is an imperative need for .

Co-localization of murine embryonic stem cell genomic sites by the master transcription factors OCT4, SOX2, and NANOG was initially highly predictive of enhancer activity.

As existing defects in cell-signaling pathways allow cancer to alter their normal programs of proliferation, transcription, growth, migration, differentiation, and death, hence reports suggest such reliance on SE-driven transcription for proliferation and survival offers a potent therapeutic mark for the targeting of .

Among many pathways of cancer progression that PDAC relies on, anomalous activation of the sonic hedgehog pathway has shown in a variety of human cancers, including, , malignant gliomas, medulloblastoma, leukemias, and cancers of the breast, lung, pancreas, and prostate.

Recent reports suggest that they can target multiple pathways and several cell types including cancer stem cells.

The Dhar research team concluded, "As mentioned earlier in spite of low incidences PDAC is the fourth leading cause of cancer-related mortality because, by the time of diagnosis, more than 80% of cases are locally advanced or distally metastasized, and are not eligible for surgical resection, which is the most effective treatment option."


Explore further

Researchers elucidate roles of TP63 and SOX2 in squamous cell cancer progression

More information: Chandrayee Ghosh et al, Super-enhancers: novel target for pancreatic ductal adenocarcinoma, Oncotarget (2019). DOI: 10.18632/oncotarget.26704
Journal information: Oncotarget

Provided by Rapamycin Press
Citation: Super-enhancers: novel target for pancreatic ductal adenocarcinoma (2019, February 27) retrieved 10 April 2020 from https://medicalxpress.com/news/2019-02-super-enhancers-pancreatic-ductal-adenocarcinoma.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
 shares

Feedback to editors

User comments